Research background · Updated November 1, 2026
FOXO4-DRI Research: Publications, Study Types and Background
Short answer
FOXO4-DRI. As of November 1, 2026, PubMed indexes 19 records matching FOXO4-DRI, the earliest from 2017; 11 were published in 2021–2025 and 5 are reviews. ClinicalTrials.gov lists 0 registered studies matching the compound.
- PubMed records
- 19
- Earliest record
- 2017
- Published 2021–2025
- 11
- Reviews
- 5
- Animal-only studies
- 5
- Registered studies
- 0
Publications per year, 2006–2025
18 records in 2016–2025 against 0 in 2006–2015; the busiest year was 2017, with 3.
See the numbers
| Year | PubMed records |
|---|---|
| 2006 | 0 |
| 2007 | 0 |
| 2008 | 0 |
| 2009 | 0 |
| 2010 | 0 |
| 2011 | 0 |
| 2012 | 0 |
| 2013 | 0 |
| 2014 | 0 |
| 2015 | 0 |
| 2016 | 0 |
| 2017 | 3 |
| 2018 | 2 |
| 2019 | 0 |
| 2020 | 1 |
| 2021 | 2 |
| 2022 | 3 |
| 2023 | 2 |
| 2024 | 2 |
| 2025 | 3 |
Study types
| All PubMed records | 19 |
|---|---|
| Reviews | 526% |
| Animal studies (no human subjects indexed) | 526% |
| Indexed as clinical trials | 00% |
| Registered on ClinicalTrials.gov | 0 |
Categories overlap and follow PubMed’s own indexing; recent records may not be indexed yet.
Primary research directions
What 1 of the most-cited and most recent FOXO4-DRI papers report, in their own authors’ terms. Each line links the paper it came from.
Senescent cell elimination
The authors designed a FOXO4 peptide that disrupts the FOXO4 and p53 interaction; in senescent cells it caused p53 to leave the nucleus and triggered apoptosis, and in mice it neutralized doxorubicin-induced chemotoxicity and restored fitness, fur density and renal function in fast-aging and naturally aged animals.
MiceBaar MP 2017CellPMID 28340339
Most-studied topics
The Medical Subject Headings (MeSH) PubMed indexers most often marked as a main topic, across 19 of the 19 records. They describe what the literature is about, not what FOXO4-DRI does.
- Forkhead Transcription Factors5 papers
- Cellular Senescence5 papers
- Cell Cycle Proteins4 papers
- Pulmonary Fibrosis3 papers
- Apoptosis3 papers
- Aging3 papers
- Tumor Suppressor Protein p533 papers
- Leydig Cells2 papers
Key papers
Earliest indexed record
Krimpenfort P (2017). Cell.
PMID 28340347Most-cited paper · 138 citations
Valentijn FA (2018). Journal of cell communication and signaling.
PMID 29260442Most-cited #2 · 135 citations
Born E (2023). Circulation.
PMID 36515093Most-cited #3 · 114 citations
Meng J (2021). JCI insight.
PMID 34877934
Citation counts from NIH iCite, among the 19 records sampled. Titles are left out; open each record on PubMed to read it.
Identity
| CAS | 2460055-10-9 |
|---|---|
| Molecular formula | C228H388N86O64 |
| Molecular weight | 5358 g/mol |
| Synonyms | FOXO4-DRI TFA salt form, FOXO4-DRI |
Identity data from PubChem, retrieved November 1, 2026, on the FOXO4-DRI page.
How these numbers were counted
- PubMed search, run November 1, 2026:
"FOXO4-DRI"[tiab] OR "FOXO4 D-Retro-Inverso"[tiab]re-run it. Study types add PubMed’s own filters (review, clinical trial, animals not humans). - Topics: MeSH major-topic headings counted across up to 400 of the matching records; headings for study set-up (species, sex, age) are left out.
- Citations: NIH iCite citation counts for the same records.
- ClinicalTrials.gov search:
"FOXO4-DRI"re-run it. Any phase, any status.
This page reports what has been published and what papers say they found, with each source linked. It gives no dosing or usage information, and nothing here is a reason to use FOXO4-DRI outside a laboratory.
Wholesale supply
FOXO4-DRI, sourced to order for research.
Not held in the listed catalog. Tell us the vial size and the number of vials and we come back with availability, documentation and pricing in writing.
FOXO4-DRI research questions
How much research has been published on FOXO4-DRI?
PubMed indexes 19 records matching FOXO4-DRI (searched November 1, 2026), including 5 reviews and 0 records indexed as clinical trials. 11 were published in the five years 2021–2025.
When was FOXO4-DRI first described in the literature?
The earliest PubMed record matching FOXO4-DRI is from 2017 (Krimpenfort P, Cell, PMID 28340347).
What topics does the FOXO4-DRI literature cover?
The subject headings PubMed indexers most often marked as a main topic of FOXO4-DRI papers are Forkhead Transcription Factors, Cellular Senescence, Cell Cycle Proteins, Pulmonary Fibrosis. These describe what the literature is about. Findings from individual papers, with their sources, are summarized on this page.
Is FOXO4-DRI sold for human use?
No. Vanta Foundry supplies it for laboratory research use only. Not for human or veterinary use, and not a drug, food, cosmetic or dietary supplement.
Where can I buy FOXO4-DRI wholesale for research?
We source FOXO4-DRI to order rather than stock it. Tell us the vial size and number of vials on WhatsApp or by email and the quote confirms availability, documentation and pricing.
Research materials supplied by Vanta Foundry are for laboratory research use only. They are not for human or veterinary use and are not drugs, foods, cosmetics or dietary supplements. Websites and payment processing are business services for research-supply brands.
All compounds: research peptide publication statistics.